The following criteria is provided for health care professionals.

Key Inclusion Criteria:

1. Newly diagnosed or relapsed multiple myeloma
2. Measurable disease by Serum M protein, or Urine M protein, or Serum quantitative immunoglobulin (qIgA) (for immunoglobulin (Ig) A subjects whose disease can only be reliably measured by qIgA)
3. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 1
4. Left ventricular ejection fraction (LVEF) ≥ 40%

Key Exclusion Criteria:

1. Waldenström macroglobulinemia
2. For newly diagnosed multiple myeloma: multiple myeloma of IgM subtype
3. For relapsed disease:
   1. If treated with a lenalidomide and dexamethasone combination, progression during the first 3 months after initiating treatment.
   2. Any progression during treatment if the lenalidomide and dexamethasone regimen was the most recent line of therapy.
   3. Any prior treatment with carfilzomib
4. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
5. Plasma cell leukemia (> 2.0 × 109/L circulating plasma cells by standard differential)
6. Myelodysplastic syndrome
7. Amyloidosis
8. Prior treatment with carfilzomib or oprozomib